1. Home
  2. CHEK vs KZIA Comparison

CHEK vs KZIA Comparison

Compare CHEK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • KZIA
  • Stock Information
  • Founded
  • CHEK 2004
  • KZIA 1994
  • Country
  • CHEK Israel
  • KZIA Australia
  • Employees
  • CHEK N/A
  • KZIA N/A
  • Industry
  • CHEK Medical Electronics
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHEK Health Care
  • KZIA Health Care
  • Exchange
  • CHEK Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • CHEK 9.0M
  • KZIA 7.8M
  • IPO Year
  • CHEK 2015
  • KZIA 1999
  • Fundamental
  • Price
  • CHEK $0.93
  • KZIA $1.29
  • Analyst Decision
  • CHEK
  • KZIA Strong Buy
  • Analyst Count
  • CHEK 0
  • KZIA 2
  • Target Price
  • CHEK N/A
  • KZIA $11.50
  • AVG Volume (30 Days)
  • CHEK 88.2K
  • KZIA 5.5M
  • Earning Date
  • CHEK 02-18-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • CHEK N/A
  • KZIA N/A
  • EPS Growth
  • CHEK N/A
  • KZIA N/A
  • EPS
  • CHEK N/A
  • KZIA N/A
  • Revenue
  • CHEK N/A
  • KZIA $1,655,324.00
  • Revenue This Year
  • CHEK N/A
  • KZIA $806.89
  • Revenue Next Year
  • CHEK N/A
  • KZIA N/A
  • P/E Ratio
  • CHEK N/A
  • KZIA N/A
  • Revenue Growth
  • CHEK N/A
  • KZIA 248000.00
  • 52 Week Low
  • CHEK $0.56
  • KZIA $1.25
  • 52 Week High
  • CHEK $3.45
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 42.16
  • KZIA 39.50
  • Support Level
  • CHEK $0.81
  • KZIA $1.31
  • Resistance Level
  • CHEK $1.00
  • KZIA $2.64
  • Average True Range (ATR)
  • CHEK 0.10
  • KZIA 0.24
  • MACD
  • CHEK -0.05
  • KZIA 0.09
  • Stochastic Oscillator
  • CHEK 13.98
  • KZIA 14.29

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: